XML 35 R22.htm IDEA: XBRL DOCUMENT
v3.21.2

MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - (Tables) | 9 Months Ended
--- | ---
Sep. 30, 2021
Novartis Institutes for BioMedical Research, Inc. |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |
Revenues Recognized under Agreement | Revenues recognized under the agreement were as follows (in thousands):
| Three Months Ended September 30, |  | Nine Months Ended September 30,
| 2021 |  | 2020 |  | 2021 |  | 2020
Revenue related to Novartis agreement: |  |  |  |  |  |  |
Recognition of upfront license fee | $ | 9,093 |  |  | $ | — |  |  | $ | 22,852 |  |  | $ | — |
Research services | 2,421 |  |  | — |  |  | 6,104 |  |  | — |
Total | $ | 11,514 |  |  | $ | — |  |  | $ | 28,956 |  |  | $ | — |
Biogen MA, Inc. |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |
Revenues Recognized under Agreement | Revenues recognized under the agreement were as follows (in thousands):
| Three Months Ended September 30, |  | Nine Months Ended September 30,
| 2021 |  | 2020 |  | 2021 |  | 2020
Revenue related to Biogen agreement: |  |  |  |  |  |  |
Recognition of license and stand-ready fee | $ | 7,306 |  |  | $ | 7,306 |  |  | $ | 21,918 |  |  | $ | 14,050 |
Research services | 3,661 |  |  | 2,315 |  |  | 10,266 |  |  | 3,749 |
Total | $ | 10,967 |  |  | $ | 9,621 |  |  | $ | 32,184 |  |  | $ | 17,799 |
Kite Pharma, Inc. |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |
Revenues Recognized under Agreement | Revenues recognized under the agreement were as follows (in thousands):
| Three Months Ended September 30, |  | Nine Months Ended September 30,
| 2021 |  | 2020 |  | 2021 |  | 2020
Revenue related to Kite agreement: |  |  |  |  |  |  |
Recognition of license and stand-ready fee | $ | 6,296 |  |  | $ | 6,296 |  |  | $ | 18,682 |  |  | $ | 18,750 |
Research services | 113 |  |  | 998 |  |  | 339 |  |  | 3,185 |
Total | $ | 6,409 |  |  | $ | 7,294 |  |  | $ | 19,021 |  |  | $ | 21,935 |
Sanofi S.A. |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |
Revenues Recognized under Agreement | Revenues recognized under the agreement were as follows (in thousands):
| Three Months Ended September 30, |  | Nine Months Ended September 30,
| 2021 |  | 2020 |  | 2021 |  | 2020
Revenue related to Sanofi agreement: |  |  |  |  |  |  |
Recognition of upfront fee | $ | (1,125) |  |  | $ | 321 |  |  | $ | (692) |  |  | $ | (28) |
Research services | 1,125 |  |  | 961 |  |  | 2,417 |  |  | 3,836 |
Milestone achievement | (759) |  |  | 216 |  |  | (467) |  |  | (19) |
Total | $ | (759) |  |  | $ | 1,498 |  |  | $ | 1,258 |  |  | $ | 3,789 |

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 808 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434 + Details
Name: | us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_CounterpartyNameAxis=sgmo_NovartisInstitutesForBioMedicalResearchIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=sgmo_BiogenMAIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=sgmo_SanofiMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |